Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 9.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 855,700 shares of the life sciences company's stock after selling 89,700 shares during the period. Two Sigma Advisers LP owned approximately 0.54% of Illumina worth $111,592,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Empowered Funds LLC raised its position in Illumina by 1.7% in the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company's stock valued at $516,000 after purchasing an additional 66 shares during the period. Caprock Group LLC raised its holdings in Illumina by 3.0% in the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company's stock valued at $376,000 after buying an additional 83 shares during the period. UMB Bank n.a. lifted its position in Illumina by 7.0% in the second quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company's stock valued at $140,000 after buying an additional 88 shares during the last quarter. Integrated Advisors Network LLC boosted its stake in Illumina by 2.0% during the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company's stock worth $585,000 after buying an additional 90 shares during the period. Finally, Moors & Cabot Inc. increased its position in shares of Illumina by 1.7% during the third quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company's stock valued at $759,000 after acquiring an additional 95 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Performance

Shares of NASDAQ ILMN traded up $0.03 during trading hours on Friday, reaching $139.94. The stock had a trading volume of 545,155 shares, compared to its average volume of 2,012,589. The firm has a market cap of $22.19 billion, a price-to-earnings ratio of -14.23 and a beta of 1.11. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The firm has a 50-day moving average of $142.90 and a 200-day moving average of $126.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion for the quarter, compared to analysts' expectations of $1.08 billion. During the same period in the previous year, the company posted $0.33 EPS. The company's quarterly revenue was down 3.5% on a year-over-year basis. Equities research analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Royal Bank of Canada lifted their target price on shares of Illumina from $252.00 to $254.00 and gave the company an "outperform" rating in a report on Tuesday, November 5th. UBS Group lifted their price objective on Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Piper Sandler decreased their target price on Illumina from $195.00 to $185.00 and set an "overweight" rating on the stock in a research note on Monday, November 11th. Citigroup lifted their target price on Illumina from $155.00 to $190.00 and gave the company a "buy" rating in a research report on Tuesday, November 5th. Finally, HSBC raised shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 price target on the stock in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $164.00.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.